ARVN Earnings

ARVN reported its earnings on 2026-02-24, showcasing a revenue of 9.50M against an estimate of 33.05M, resulting in a -71.26% surprise. The EPS was -1.1, surpassing the expected -0.55 by -100%. The stock experienced a 0.57% price change on the earnings day and a 7.89% change over the next five days, reflecting market reactions to the results.

Following ARVN's earnings announcement on 2026-02-24, the stock price moved by 0.57% on the day of the release. Over the subsequent five days, it saw a 7.89% change. Historically, ARVN's stock price tends to shift by an average of 4.42% in the 10 days leading up to earnings and 1.61% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ARVN's annual revenue to reach 21.89M, while the EPS is projected at -0.78. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ARVN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARVN's stock price typically moves by 4.42% in the 10 days before its earnings and 1.61% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.78 and revenue of 21.89M.

The company shows strong financial health with a substantial stock repurchase program, promising product development with multiple trials and a potential FDA approval, and a strategic plan for commercialization. While there are some uncertainties in timelines and regulatory feedback, the overall outlook is optimistic. The market cap suggests moderate volatility, but the positive developments, particularly in clinical trials and regulatory milestones, are likely to outweigh the uncertainties, resulting in a positive stock price movement.